Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

and development programs at the following events:

  • April 12 to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research (AACR) in Denver, CO.
  • April 24, 2009: Micromet will hold an R&D meeting in New York, NY for investors and analysts to provide a review of its product pipeline.
  • May 29 to June 5, 2009: Update on a phase 1b clinical trial combining adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of the American Society for Clinical Oncology (ASCO) in Orlando, FL.
  • June 4 to 7, 2009: Update on the phase 2 clinical trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.
  • September 20 to 24, 2009: First interim data from a phase 1 clinical trial with MT110, an EpCAM-targeting BiTE antibody, in patients with metastatic gastrointestinal and lung cancers at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany.
  • December 5 to 8, 2009: Update on a phase 2 clinical trial with blinatumomab in ALL patients and final results from a phase 1 clinical trial in late stage NHL patients at the annual meeting of the American Society for Hematology (ASH) in New Orleans, LA.

Additional expected Milestones in 2009:

  • In the first half of 2009, we expect to initiate a randomized, controlled, multicenter phase 2 clinical trial for relapsed colorectal cancer patients after complete resection of liver metastasis with adecatumumab, an EpCAM-targeting human monoclonal antibody that we develop in collaboration with Merck Serono;
  • Before the end of 2009, we plan to initiate an additional p
    '/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Today, TiFiber, Inc. ... production facility and future company headquarters in Fort ... new materials that safely and effectively control dangerous ... of its historic, strong support for manufacturing, but ... leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq: VRNM ), a pioneer in the ... that it has renewed and extended its joint marketing ... heat transfer, separation and fluid handling technologies, for Purifine® ... agreement to jointly market enzymatic degumming of vegetable oils ...
... SEATTLE, Oct. 26 On Thursday, October ... Central European/5:30 a.m. Pacific, members of Cell ... management team will host a conference call ... financial results.Conference Call NumbersThursday, October 288:30 a.m. ...
... Tengion, Inc. (Nasdaq: TNGN ), a ... Saturday, October 23, 2010 in a podium presentation ... Exchange in Orlando, FL. The presentation highlighted new ... demonstrating promising improvements in kidney function with an ...
Cached Biology Technology:Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 3Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 4Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference 2Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference 3Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference 4
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... , Sept. 18, 2013 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p01623686/Emerging-Opportunities-in-Global-Biometrics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... Manifold,This study analyzes the emerging applications in ...
...  GenesisSolutions (An ABS Group Company), a Fully Integrated Global ... Sciences EAM Symposium for Engineering, Maintenance & Reliability professionals ... in Cary, North Carolina . ... provide participants with examples of Asset Management Best Practices ...
... study led by researchers at Children,s National Medical Center ... promise for the treatment of Duchenne muscular dystrophy (DMD). ... , show that the drug, VBP15, decreases inflammation ... effects linked to current treatments with glucocorticoids such as ...
Cached Biology News:Emerging Opportunities in Global Biometrics Market 2Emerging Opportunities in Global Biometrics Market 3Emerging Opportunities in Global Biometrics Market 4Emerging Opportunities in Global Biometrics Market 5Life Sciences EAM Symposium 2Life Sciences EAM Symposium 3New muscular dystrophy treatment shows promise in early study led by Children's National 2
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: